Evaluation of results of living donor liver transplantation for hepatocellular carcinoma

  • Le Van Thanh 108 Military Central Hospital
  • Vũ Văn Quang Bệnh viện Trung ương Quân đội 108
  • Nguyễn Mạnh Dũng Bệnh viện Trung ương Quân đội 108
  • Hồ Văn Linh
  • Lê Trung Hiếu Bệnh viện Trung ương Quân đội 108
  • Vũ Ngọc Tuấn Bệnh viện Trung ương Quân đội 108
  • Lê Văn Lợi Bệnh viện Trung ương Quân đội 108
  • Nguyễn Hoàng Ngọc Anh Bệnh viện Trung ương Quân đội 108
  • Mai Hồng Bàng Bệnh viện Trung ương Quân đội 108

Main Article Content

Keywords

Liver Transplantatation, Living Donor Liver Transplantation (LDLT), HCC

Abstract

Objective: To evaluate the results of living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) in 108 Military Central Hospital. Subject and method: Retrospective study of 55 patients with hepatocellular carcinoma who received living donor liver transplantation from October 2017 to June 2022 in 108 Military Central Hospital. Result: 56.4% met the UCSF criteria, and 43.6% met the Milan criteria. The number of patients with complications was 19 (34.5%) patients, with no cases of postoperative mortality. The 1-year and 3-year overall survival and disease-free survival rates were 95.7%, 89.7% and 90.6%, 86.6%, respectively. HCC recurrence was 9 (16.4%) patients. Conclusion: Living donor Liver transplantation for HCC is a safe and effective method.

Article Details

References

1. Yoon Y.-I, Lee S.-G (2019). Living donor liver transplantation for patients with hepatocellular carcinoma: An Asian Perspective. Dig Dis Sci Apr; 64(4) ; 993-1000.
2. Busuttil RW, Klintmalm BG (2015). Transplantation of the liver. Elsevier, Third Edition.
3. Nguyễn Quang Nghĩa (2017). Ghép gan từ người hiến sống. Nhà xuất bản Y học.
4. Sugawara Y, Yamamoto H, Hibi T (2018). Living donor liver transplantation for patients with hepatocellular carcinoma in Japan, Hepatoma Res; 4:33.
5. Lee SG, Anh CS, Ha TY, et al (2010): Living donor liver transplantation for hepatocellular carcinoma: Korean experience.
6. Liang HR, Hsieh CE, Ko CJ, Hung YJ, Hsu YL, Chen YL (2021). Living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria: outcome of expanded criteria in tumor size.
7. Mok JH, Ma KM, Chok KSH (2022). Experience of living donor liver transplantation for hepatocellular carcinoma in the University of Hong Kong Hospital. Hepatoma Res; 8:6.
8. Koc S, Akbulut S, Soyer V, et al (2021). Hepatic Outflow Obstruction after living donor liver transplant: Single center experience. Experimental and Clinical Transplantation; 8: 832-841.
9. Kim KS, Lee JS, et al (2018). Long-term outcomes after stent insertion in patients with early and late hepatic vein outflow obstruction after living donor liver transplantation.
10. Wang S, Lee SG, Sung , Park KM, et al (2006). Long-term icidence, risk factors, and management of biliary complications after adult living donor liver transplantation. Liver Transpl; 12(5): 831-838.

Article Sidebar

PDF (Tiếng Việt)
Published
Jul 11, 2022
DOI: https://doi.org/10.52389/ydls.v17iDB.1257
Issue
Volume 17 - Special Issue 7/2022: The 2nd National Scientific Conference on Liver Cancer
Section
Articles
How to Cite
Van ThanhL., QuangV. V., DũngN. M., LinhH. V., HiếuL. T., TuấnV. N., LợiL. V., AnhN. H. N., & BàngM. H. (2022). Evaluation of results of living donor liver transplantation for hepatocellular carcinoma. Tạp Chí Y Dược lâm sàng 108, 17(DB). https://doi.org/10.52389/ydls.v17iDB.1257